Although the mechanisms involved in the immunogenicity of biologic agents are not fully elucidated, anti-TNF in combination with MTX is considered to be a gold standard therapy for moderate to severe RA patients [64]. The gene discussed is TNF; the disease is rheumatoid arthritis.